Clinical Trial Update: Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ofatumumab and bortezomib in adults with relapsed CD20-positive lymphomas, including diffuse large B-cell lymphoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Ofatumumab (Arzerra) (Ofatumumab)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2014-07-30